Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) announced better-than-expected revenue in Q3 2026, with revenue up 8.2% year on year to $207.6 million. Its non-GAAP profit of $1.14 per share was 32.8% above analysts’ consensus estimates.

For more on Amphastar Pharmaceuticals, read the full research report for free.

"Our third quarter results demonstrate the strength of Amphastar's diversified portfolio and the commercial platform we have built. Record sales of BAQSIMI® and Primatene MIST®, together with contributions from recently launched products, supported continued revenue growth and further strengthened the foundation for our long-term strategy. During the quarter, we continued to advance programs across our complex generic, biosimilar, and proprietary pipelines while investing in the manufacturing, quality and development capabilities needed to support future growth. We remain focused on disciplined execution, strengthening our operations, and deploying capital in ways that we believe can create sustainable long-term value for our shareholders," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer.

Revenue growth

A company’s long-term revenue performance can indicate its overall quality. Any business can report a good quarter or two, but many enduring ones grow for years. Amphastar Pharmaceuticals’s 12.6% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth matters most, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Amphastar Pharmaceuticals’s recent performance shows its demand has slowed as its annualized revenue growth of 1.5% over the last two years was below its five-year trend. Decelerating revenue growth in the sector warrants caution, as it could signal changing consumer tastes aided by low switching costs.

This quarter, Amphastar Pharmaceuticals reported year-on-year revenue growth of 8.2%, and its $207.6 million of revenue exceeded Wall Street’s consensus estimates by 5.9%.

Looking ahead, sell-side analysts expect revenue to grow 4.6% over the next 12 months, according to S&P. While this projection implies its newer products and services will drive better revenue performance, it is still below the sector average.

Adjusted operating margin

Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses, from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt and taxes.

Amphastar Pharmaceuticals has performed well over the last five years. It demonstrated high profitability for a healthcare business, with an average adjusted operating margin of 30.6%.

Looking at the trend in its profitability, Amphastar Pharmaceuticals’s adjusted operating margin rose by 1.9 percentage points over the last five years, as its revenue growth gave it operating leverage. More recently, however, the company’s margin has decreased by 10.9 percentage points on a two-year basis. To meet the benchmark, Amphastar Pharmaceuticals must prove it can expand its profitability consistently.

In Q3, Amphastar Pharmaceuticals generated an adjusted operating margin of 27.8%, down 4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings per share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its revenue through excessive spending on advertising and promotions.

Amphastar Pharmaceuticals’s EPS grew at a 23.8% compounded annual growth rate over the last five years, higher than its 12.6% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

Examining Amphastar Pharmaceuticals’s quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Amphastar Pharmaceuticals’s adjusted operating margin declined this quarter but expanded by 1.9 percentage points over the last five years. Its share count also shrank by 13.3%, and these factors together are positive signs for shareholders because improving profitability and share buybacks boost EPS growth relative to revenue growth.

In Q3, Amphastar Pharmaceuticals reported adjusted EPS of $1.14, up from $0.93 in the same quarter last year. The result was well above analysts’ consensus estimates, a positive for shareholders. Over the next 12 months, Wall Street expects Amphastar Pharmaceuticals’s full-year EPS to stay about the same, moving from $3.20 to $3.22, according to S&P.

Key takeaways from Amphastar Pharmaceuticals’s Q3 results

Amphastar Pharmaceuticals delivered a solid quarter, with revenue beating Wall Street’s consensus estimates by a wide margin and EPS also topping analysts’ consensus expectations. Shares surged 7.2% to $29.66 immediately after the results.

Amphastar Pharmaceuticals had a good quarter, but that alone does not determine whether to invest. That decision also calls for a look at valuation and business quality alongside the latest earnings. Read more in our full research report here (it’s free).